Form 4: Avenue Therapeutics Director Jay D. Kranzler Acquires 30,000 Employee Stock Options
SEC Form 4
Director Jay D. Kranzler reports acquisition of 30,000 employee stock options in Avenue Therapeutics, Inc.
Summary
- On September 23, 2024, Jay D. Kranzler, a director of Avenue Therapeutics, Inc., acquired 30,000 employee stock options.
- The exercise price of these options is $2.46.
- The options vest in three equal installments on January 1, 2025, January 1, 2026, and January 1, 2027.
- The options expire on September 23, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither inherently positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 09/23/2024 | Date of transaction: Jay D. Kranzler acquired 30,000 employee stock options. |
| 01/01/2025 | One-third of the options vest. |
| 01/01/2026 | One-third of the options vest. |
| 01/01/2027 | One-third of the options vest. |
| 09/23/2034 | Expiration date of the options. |
| 09/25/2024 | Date of signature on the Form 4 filing. |
Keywords
Avenue Therapeutics, ATXI, Form 4, insider trading, stock options, director, Jay D. Kranzler
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.